Diabetic kidney disease (DKD) is an inflammatory disease caused by metabolic disorder. As an important signaling pathway in the inflammatory response, the JNK signaling pathway plays an crucial role in kidney injury in DKD. Vitamin D3 can reduce the inflammatory reaction and delay or even reverse DKD progression. Unfortunately, the mechanism by which vitamin D3 regulates DKD pathogenesis is unclear. This research established a DKD rat model and vitamin D3 and irbesartan were used as interventions. Then, urine and blood biochemistry; and inflammatory cytokine (IL-1 and IL-6), phosphorylated JNK pathway protein (MEK-4 and JNK1/2/3) and downstream factor (AP-1 and ATF-2) expression were assessed. We found that the DKD group showed body weight and insulin secretion were significantly decreased; significantly increased FPG, HOMA-IR and blood lipids; and significantly increased 24-h urinary protein (UPro) compared with normal group. Additionally, the levels of IL-1 and IL-6 and phosphorylated JNK pathway proteins were significantly elevated. These changes were improved by vitamin D3, especially at a low dosage. These results suggest that active vitamin D3 protects against DKD in rats by reducing IL-6 and IL-1 release, downregulating the JNK inflammatory signaling pathway, and inhibiting downstream transcription factor AP-1- and ATF-2-mediated kidney damage. This research provides a new theoretical support for vitamin D3 treatment of diabetic nephropathy.
| Published in | International Journal of Diabetes and Endocrinology (Volume 6, Issue 3) |
| DOI | 10.11648/j.ijde.20210603.13 |
| Page(s) | 105-113 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
Diabetic Kidney Disease (DKD), Active Vitamin D3, IL-1, IL-6, JNK
| [1] | Reutens AT, Atkins RC. (2011). Epidemiology of diabetic nephropathy. Contrib Nephrol, 170: 1-7. |
| [2] | Elmarakby AA, Sullivan JC. (2012). Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther, 30: 49-59. |
| [3] | Celec P, Hodosy J, Gardlik R, et al. (2012). The effects of anti-inflammatory and anti-angiogenic DNA vaccination on diabetic nephropathy in rats. Hum Gene Ther, 23: 158-166. |
| [4] | Mohan T, Velusamy P, Chakrapani LN, et al. (2012). Impact of EGCG Supplementation on the Progression of Diabetic Nephropathy in Rats: An Insight into Fibrosis and Apoptosis. J Agric Food Chem, 65: 8028-8036. |
| [5] | Krieken RV, Krepinsky JC. (2017). Caveolin-1 in the Pathogenesis of Diabetic Nephropathy: Potential Therapeutic Target? Curr Diab Rep, 17: 19. |
| [6] | Wang Y, Wang Y, Luo M, et al. (2015). Novel curcumin analog C66 prevents diabetic nephropathy via JNK pathway with the involvement of p300/CBP-mediated histone acetylation. Biochim Biophys Acta, 1852: 34-46. |
| [7] | Sun XY, Qin HJ, Zhang Z, et al. (2016). Valproate attenuates diabetic nephropathy through inhibition of endoplasmic reticulum stress-induced apoptosis. Mol Med Rep, 13: 661-668. |
| [8] | Anders HJ, Huber TB, Isermann B, et al. (2018). CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol, 14: 361-377. |
| [9] | Abdelhafiz AH. (2020). Diabetic Kidney Disease in Older People with Type 2 Diabetes Mellitus: Improving Prevention and Treatment Options. Drugs Aging, 37: 567-584. |
| [10] | Galkina E, Ley K. (2006). Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol, 17: 368-377. |
| [11] | Chow F, Ozols E, Nikolic-Paterson DJ, et al. (2004). Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int, 65: 116-128. |
| [12] | Chow FY, Nikolic-Paterson DJ, Atkins RC, et al. (2004). Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant, 19: 2987-2996. |
| [13] | King GL. (2008). The role of inflammatory cytokines in diabetes and its complications. J Periodontol, 79: 1527-1534. |
| [14] | Catalan V, Gomez-Ambrosi J, Ramirez B, et al. (2007). Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg, 17: 1464-1474. |
| [15] | Kim CS, Park HS, Kawada T, et al. (2006). Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes, 30: 1347-1355. |
| [16] | Duran-Salgado MB, Rubio-Guerra AF. (2014). Diabetic nephropathy and inflammation. World J Diabetes, 5: 393-398. |
| [17] | Tian Y, Lv G, Yang Y, et al. (2014). Effects of vitamin D on renal fibrosis in diabetic nephropathy model rats. Int J Clin Exp Pathol, 7: 3028-3037. |
| [18] | Wittmann S, Daniel C, Stief A, et al. (2009). Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. Transplantation, 87: 1290-1299. |
| [19] | Wu Y, Dong J, Yuan L, et al. (2008). Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy. Cytokine, 44: 85-91. |
| [20] | Ohashi N, Urushihara M, Satou R, et al. (2010). Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen species--ERK/JNK pathways. Hypertens Res, 33: 1174-1181. |
| [21] | Pan Y, Wang Y, Zhao Y, et al. (2014). Inhibition of JNK phosphorylation by a novel curcumin analog prevents high glucose-induced inflammation and apoptosis in cardiomyocytes and the development of diabetic cardiomyopathy. Diabetes, 63: 3497-3511. |
| [22] | Ferdaoussi M, Abdelli S, Yang JY, et al. (2008). Exendin-4 Protects β-Cells From Interleukin-1β-Induced Apoptosis by Interfering With the c-Jun NH2-Terminal Kinase Pathway. Diabetes, 57: 1205-1215. |
| [23] | Li YC, Samuvel DJ, Sundararaj KP, et al. (2010). IL-6 and high glucose synergistically upregulate MMP-1 expression by U937 mononuclear phagocytes via ERK1/2 and JNK pathways and c-Jun. J Cell Biochem, 110: 248-259. |
| [24] | Davis WRJ. (2007). The JNK signal transduction pathway. Cur Opin Cell Biol, 19: 142-149. |
| [25] | Park MJ, Bae CS, Lim SK, et al. (2010). Effect of protopanaxadiol derivatives in high glucose-induced fibronectin expression in primary cultured rat mesangial cells: role of mitogen-activated protein kinases and Akt. Arch Pharm Res, 33: 151-157. |
| [26] | Lee GS. (2005). Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: focus on hypertension and proteinuria. Ann Acad Med Singap, 34: 24-30. |
| [27] | Luisrodriguez D, Martinezcastelao A, Gorriz JL, et al. (2012). Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. World J Diabetes, 3: 7-18. |
| [28] | Kim OS, Kim YS, Jang DS, et al. (2009). Cytoprotection against hydrogen peroxide-induced cell death in cultured mouse mesangial cells by erigeroflavanone, a novel compound from the flowers of Erigeron annuus. Chem Biol Interact, 180: 414-420. |
| [29] | Pan Y, Zhu G, Wang Y, et al. (2013). Attenuation of high-glucose-induced inflammatory response by a novel curcumin derivative B06 contributes to its protection from diabetic pathogenic changes in rat kidney and heart. J Nutr Biochem, 4: 146-155. |
| [30] | Jiang W, Li Z, Zhao W, et al. (2016). Breviscapine attenuatted contrast medium-induced nephropathy via PKC/Akt/MAPK signalling in diabetic mice. Am J Transl Res, 8: 329-341. |
| [31] | Kikkawa R, Koya D, Haneda M. (2003). Progression of diabetic nephropathy. Am J Kidney Dis, 41: S19-21. |
| [32] | Yang H, Kan QE, Su Y, et al. (2018). Long Non-Coding RNA CASC2 Improves Diabetic Nephropathy by Inhibiting JNK Pathway. Exp Clin Endocrinol Diabetes, 127: 533-537. |
| [33] | Gao P, Wei Y, Zhang Z, et al. (2016). Synergistic effects of c-Jun and SP1 in the promotion of TGFβ1-mediated diabetic nephropathy progression. Exp Mol Pathol, 100: 441-450. |
| [34] | Weldegiorgis TZ, Hidru TH, Yang XL, et al. (2020). Association between serum 25-hydroxyvitaminD concentrations and metabolic syndrome in the middle-aged and elderly Chinese population in Dalian, northeast China: A cross-sectional study. J Diabetes Investig, 11: 184-191. |
| [35] | Zang L, Fu P, Huang YQ, et al. (2012). Vitamin D deficiency and carotid artery intima-media thickness and coronary calcification in patients with diabetic nephropathy. Journal of Sichuan University (Medical Science Edition), 43: 420-424 (In Chinese). |
| [36] | Halteren AGSV, Tysma OM, Etten EV, et al. (2004). 1alpha, 25-dihydroxy vitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun, 23: 233-239. |
| [37] | Navarro-Gonzalez JF, Donate-Correa J, Mendez ML, et al. (2013). Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study. J Clin Pharmacol, 53: 421-426. |
| [38] | Agarwal R, Acharya M, Tian J, et al. (2005). Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int, 68: 2823-2828. |
| [39] | Felicio JS, Oliveira AF, Peixoto AS, et al. (2017). Albuminuria reduction after high dose of vitamin D in patients with type 1 diabetes mellitus: a pilot study. Front Endocrinol, 8: 199. |
| [40] | Makibayashi K, Tatematsu M, Hirata M, et al. (2001). A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol, 158: 1733-1741. |
| [41] | Yang MX, Shen ZN, Chen DY, et al. (2012). Effects of 1, 25-(OH)2D3 on the expressions of vitamin D receptor, STAT5 and cytoskeletal rearrangement in human monocytes incubated with sera from type 2 diabetes patients and diabetic nephropathy patients with uremia. Inflamm Res, 61: 511-520. |
| [42] | Liu LN, Lv GD, Ning CH, et al. (2016). Therapeutic effects of 1, 25-dihydroxyvitamin D3 on diabetes-induced liver complications in a rat model. Exp Ther Med, 11: 2284-2292. |
| [43] | Xing DJ, Xu SZ, Cheng GY, et al. (2014). Comparison on Diabetic Nephropathy Rat Model Building. Journal of Liaoning University of Tradition Chinese Medicine, 16: 102-104 (In Chinese). |
| [44] | Zhi M, Hu LY, Xu PR. (2012). Establishment of Rat Model of Type 2 Diabetic Nephropathy and its Pathological Structural Changes. Xinjiang Medical Journal, 42: 13-17 (In Chinese). |
| [45] | Lee TN, Alborn WE, Knierman MD, et al. (2006). The diabetogenic antibiotic streptozotocin modifies the tryptic digest pattern for peptiedes of the enzyme O-GlcN Ac-selective N-acetyl-betad-glucosaminidase that contain amino acid residues essential for enzymatic activity. Biochem Pharmacol, 72: 710-718. |
| [46] | Qie HQ, Wu Y, Cheng LN, et al. (2010). Effect of irbesrtan on interleukin 6 and C reactive protein. Med J West China, 22: 1986-1991 (In Chinese). |
| [47] | Biagetti B, Aulinas A, Casteras A, et al. (2021). HOMA-IR in acromegaly: a systematic review and meta-analysis. Pituitary, 24 (2): 146-158. |
| [48] | Chen XW, Du XY, Wang YX, et al. (2016). Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-κB Pathway in Type 2 Diabetic db/db Mice. Mediators Inflamm, 1405924. |
| [49] | Wang CY, Min CY, Rong XL, et al. (2015). Irbesartan can improve blood lipid and the kidney function of diabetic nephropathy. Discov Med, 20 (108): 67-77. |
| [50] | Hager MR, Narla AD, Tannock LR. (2017). Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord, 18 (1): 29-40. |
| [51] | Colhoun HM, Betteridge DJ, Durrington PN, et al. (2009). Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis, 54 (5): 810-9. |
| [52] | Chen SC, Hung CC, Tsai YC, et al. (2013). Association of cholesterol levels with mortality and cardiovascular events among patients with CKD and different amounts of proteinuria. Clin J Am Soc Nephrol, 8 (11): 1915-26. |
| [53] | Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G, et al. (2017). Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig, 8 (1): 6-18. |
| [54] | Major GC, Alarie F, Dore J, et al. (2007). Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr, 85: 54-59. |
| [55] | Sterling KA, Eftekhari P, Girndt M, et al. (2012). The immunoregulatory function of vitamin D: Implications in chronic kidney disease. Nat Rev Nephrol, 8: 403-412. |
| [56] | Elseweidy MM, Amin RS, Atteia HH, et al. (2017). Vitamin D3 intake as regulator of insulin degrading enzyme and insulin receptor phosphorylation in diabetic rats. Biomed Pharmacother, 85: 155-159. |
| [57] | Li YC. (2013). Vitamin D receptor signaling in renal and cardiovascular protection. Semin Nephrol, 33 (5): 433-47. |
| [58] | Chen J, Hou XF, Wang G, et al. (2013). Terpene glycoside component from Moutan Cortex ameliorates diabetic nephropathy by regulating endoplasmic reticulum stress-related inflammatory responses. J ethnopharmacol, 193: 433-444. |
| [59] | Li ZZ, Hong Z, Peng ZQ, et al. (2018). Acetylshikonin from Zicao ameliorates renal dysfunction and fibrosis in diabetic mice by inhibiting TGF-β1/Smad pathway. Hum Cell, 31: 199-209. |
| [60] | Li Q, Wu T. (2017). Effect of high dosage of vitamin D3 on Cardiovascular and renal pathological change in rats. Modern Journal of Integrated Traditional Chinese and Western Meidicine, 16: 3630-3632 (In Chinese). |
| [61] | Fan XJ, Han R, Wu Y. (2020). Study on the renal protective mechanism of active vitamin D3 through regulating NF-кB signaling pathway in type 2 diabetic kidney disease rats. Journal of Chongqing Medical University, 45: 343-349 (In Chinese). |
APA Style
Xiaoju Fan, Linlin Liu, Wenzhuo Zhu, Yumei Zhao, Haowei Zhang, et al. (2021). Active Vitamin D3 Protects Against Diabetic Kidney Disease by Regulating the JNK Signaling Pathway in Rats. International Journal of Diabetes and Endocrinology, 6(3), 105-113. https://doi.org/10.11648/j.ijde.20210603.13
ACS Style
Xiaoju Fan; Linlin Liu; Wenzhuo Zhu; Yumei Zhao; Haowei Zhang, et al. Active Vitamin D3 Protects Against Diabetic Kidney Disease by Regulating the JNK Signaling Pathway in Rats. Int. J. Diabetes Endocrinol. 2021, 6(3), 105-113. doi: 10.11648/j.ijde.20210603.13
AMA Style
Xiaoju Fan, Linlin Liu, Wenzhuo Zhu, Yumei Zhao, Haowei Zhang, et al. Active Vitamin D3 Protects Against Diabetic Kidney Disease by Regulating the JNK Signaling Pathway in Rats. Int J Diabetes Endocrinol. 2021;6(3):105-113. doi: 10.11648/j.ijde.20210603.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijde.20210603.13,
author = {Xiaoju Fan and Linlin Liu and Wenzhuo Zhu and Yumei Zhao and Haowei Zhang and Yang Wu and Jia Fu and Hongmin Liang and Rui Han},
title = {Active Vitamin D3 Protects Against Diabetic Kidney Disease by Regulating the JNK Signaling Pathway in Rats},
journal = {International Journal of Diabetes and Endocrinology},
volume = {6},
number = {3},
pages = {105-113},
doi = {10.11648/j.ijde.20210603.13},
url = {https://doi.org/10.11648/j.ijde.20210603.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20210603.13},
abstract = {Diabetic kidney disease (DKD) is an inflammatory disease caused by metabolic disorder. As an important signaling pathway in the inflammatory response, the JNK signaling pathway plays an crucial role in kidney injury in DKD. Vitamin D3 can reduce the inflammatory reaction and delay or even reverse DKD progression. Unfortunately, the mechanism by which vitamin D3 regulates DKD pathogenesis is unclear. This research established a DKD rat model and vitamin D3 and irbesartan were used as interventions. Then, urine and blood biochemistry; and inflammatory cytokine (IL-1 and IL-6), phosphorylated JNK pathway protein (MEK-4 and JNK1/2/3) and downstream factor (AP-1 and ATF-2) expression were assessed. We found that the DKD group showed body weight and insulin secretion were significantly decreased; significantly increased FPG, HOMA-IR and blood lipids; and significantly increased 24-h urinary protein (UPro) compared with normal group. Additionally, the levels of IL-1 and IL-6 and phosphorylated JNK pathway proteins were significantly elevated. These changes were improved by vitamin D3, especially at a low dosage. These results suggest that active vitamin D3 protects against DKD in rats by reducing IL-6 and IL-1 release, downregulating the JNK inflammatory signaling pathway, and inhibiting downstream transcription factor AP-1- and ATF-2-mediated kidney damage. This research provides a new theoretical support for vitamin D3 treatment of diabetic nephropathy.},
year = {2021}
}
TY - JOUR T1 - Active Vitamin D3 Protects Against Diabetic Kidney Disease by Regulating the JNK Signaling Pathway in Rats AU - Xiaoju Fan AU - Linlin Liu AU - Wenzhuo Zhu AU - Yumei Zhao AU - Haowei Zhang AU - Yang Wu AU - Jia Fu AU - Hongmin Liang AU - Rui Han Y1 - 2021/08/13 PY - 2021 N1 - https://doi.org/10.11648/j.ijde.20210603.13 DO - 10.11648/j.ijde.20210603.13 T2 - International Journal of Diabetes and Endocrinology JF - International Journal of Diabetes and Endocrinology JO - International Journal of Diabetes and Endocrinology SP - 105 EP - 113 PB - Science Publishing Group SN - 2640-1371 UR - https://doi.org/10.11648/j.ijde.20210603.13 AB - Diabetic kidney disease (DKD) is an inflammatory disease caused by metabolic disorder. As an important signaling pathway in the inflammatory response, the JNK signaling pathway plays an crucial role in kidney injury in DKD. Vitamin D3 can reduce the inflammatory reaction and delay or even reverse DKD progression. Unfortunately, the mechanism by which vitamin D3 regulates DKD pathogenesis is unclear. This research established a DKD rat model and vitamin D3 and irbesartan were used as interventions. Then, urine and blood biochemistry; and inflammatory cytokine (IL-1 and IL-6), phosphorylated JNK pathway protein (MEK-4 and JNK1/2/3) and downstream factor (AP-1 and ATF-2) expression were assessed. We found that the DKD group showed body weight and insulin secretion were significantly decreased; significantly increased FPG, HOMA-IR and blood lipids; and significantly increased 24-h urinary protein (UPro) compared with normal group. Additionally, the levels of IL-1 and IL-6 and phosphorylated JNK pathway proteins were significantly elevated. These changes were improved by vitamin D3, especially at a low dosage. These results suggest that active vitamin D3 protects against DKD in rats by reducing IL-6 and IL-1 release, downregulating the JNK inflammatory signaling pathway, and inhibiting downstream transcription factor AP-1- and ATF-2-mediated kidney damage. This research provides a new theoretical support for vitamin D3 treatment of diabetic nephropathy. VL - 6 IS - 3 ER -
Information
Email: